DRR168510
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.440
- E2F_TARGETS+0.410
- PANCREAS_BETA_CELLS+0.410
- G2M_CHECKPOINT+0.370
- CHOLESTEROL_HOMEOSTASIS+0.330
- INTERFERON_GAMMA_RESPONSE+0.310
- SPERMATOGENESIS+0.300
- KRAS_SIGNALING_DN+0.290
- MTORC1_SIGNALING+0.140
- MYC_TARGETS_V2+0.130
Top 10 suppressed
- TGF_BETA_SIGNALING-0.580
- NOTCH_SIGNALING-0.560
- PROTEIN_SECRETION-0.440
- UV_RESPONSE_DN-0.400
- ADIPOGENESIS-0.380
- ANGIOGENESIS-0.360
- WNT_BETA_CATENIN_SIGNALING-0.340
- ANDROGEN_RESPONSE-0.230
- OXIDATIVE_PHOSPHORYLATION-0.220
- PEROXISOME-0.210
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR12202495 | — | — | 0.749 |
| 2 | SRR1797265 | — | cohortSC | 0.728 |
| 3 | R219 | — | — | 0.721 |
| 4 | SRR12202420 | — | — | 0.703 |
| 5 | TCGA-56-A49D-01A-11R-A24H-07 | — | cohortSQ1 | 0.700 |
| 6 | SRR25617831 | — | D | 0.700 |
| 7 | C3L-02654 | — | cohortA1 | 0.694 |
| 8 | R217 | — | — | 0.692 |
| 9 | MNG1269 | — | — | 0.691 |
| 10 | SRR1516037 | — | — | 0.688 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 21 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.440 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.410 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.410 | Cobimetinib | — uncovered |
| G2M_CHECKPOINT | 0.370 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.330 | Remibrutinib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.310 | Idelalisib | — uncovered |
| SPERMATOGENESIS | 0.300 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.290 | Remibrutinib | — uncovered |
| MTORC1_SIGNALING | 0.140 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.130 | Idelalisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.100 | Idelalisib | — uncovered |
| HYPOXIA | 0.090 | Idelalisib | — uncovered |
| UV_RESPONSE_UP | 0.080 | Idelalisib | — uncovered |
| GLYCOLYSIS | 0.070 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.060 | Idelalisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.060 | Idelalisib | — uncovered |
| KRAS_SIGNALING_UP | 0.060 | Inavolisib | — uncovered |
| COAGULATION | 0.050 | Binimetinib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.030 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.020 | Inavolisib | — uncovered |